Anonymous ID: 7b12c7 Oct. 2, 2021, 1:38 a.m. No.14704869   🗄️.is đź”—kun

>>14704848

 

Drug patents: the evergreening problem

Roger Collier

CMAJ June 11, 2013 185 (9) E385-E386; DOI: https://doi.org/10.1503/cmaj.109-4466

 

ArticleMetricsResponses

PDF

 

As any would-be inventor knows, coming up with something the world has never seen before can be tough. Tweaking something old and calling it new, on the other hand, is considerably easier.

 

In the pharmaceutical trade, when brand-name companies patent “new inventions” that are really just slight modifications of old drugs, it’s called “evergreening.” And it’s a practice that, according to some who have looked into it, isn’t doing a whole lot to improve people’s health.

 

“Typically, when you evergreen something, you are not looking at any significant therapeutic advantage. You are looking at a company’s economic advantage,” says Dr. Joel Lexchin, a professor in the School of Health Policy and Management at York University in Toronto, Ontario.

 

more . .

 

https://www.cmaj.ca/content/185/9/E385